Recurrent Prostate Cancer
116
10
16
67
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
45 trials with published results (39%)
Research Maturity
67 completed trials (58% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.8%
16 terminated out of 116 trials
80.7%
-5.8% vs benchmark
3%
4 trials in Phase 3/4
67%
45 of 67 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 67 completed trials
Clinical Trials (116)
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
Partial Prostate Salvage High Dose Rate Brachytherapy
Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy
Treatment of Locally Recurrent Prostate Cancer
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
Tumor Microenvironment Analysis of Prostate Cancer Metastasis